Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study

Alexandra Rezazadeh, Aniko Szabo, Arushi Khurana, David J. Inwards, Matthew A. Lunning, Nancy L. Bartlett, Paolo F. Caimi, Thomas D. Rodgers, Paul M. Barr, Sayan Mullick Chowdhury, Narendranath Epperla, Hiruni Mendries, Brian T. Hill, Timothy S. Oh, Reem Karmali, Julie E. Chang, Gaurav Goyal, Benjamin M. Parsons, Krista M. Isaac, Craig A. PortellKathleen Monahan, Malika Siker, David M. King, Timothy S. Fenske

Research output: Contribution to journalArticlepeer-review

Abstract

Primary bone diffuse large B-cell lymphoma is a rare variant of extranodal non-Hodgkin lymphoma historically treated with induction chemotherapy followed by consolidative radiation therapy (RT). It remains unknown whether RT confers additional benefit following rituximab-based chemoimmunotherapy (CIT) induction in patients with limited stage disease. We conducted a multicenter, retrospective analysis of patients treated between 2005 and 2019 using rituximab-based CIT regimens with or without consolidative RT to discern whether consolidative RT adds benefit in patients with stage I-II disease that could be encompassed in one radiation field. A total of 112 patients were included: 78 received CIT and radiation (RT group), and 34 received CIT alone (no RT group). The overall survival at 10 years was 77.9% in the RT group and 89.0% in the no RT group (P=0.42). The relapse-free survival at 10 years was 73.5% in the RT group and 80.3% in the no RT group (P=0.88). Neither improved overall survival nor relapse-free survival was associated with the addition of consolidative RT. Subgroup analysis of patients only achieving a partial response after CIT suggests that these patients may benefit from consolidative RT.

Original languageEnglish
Pages (from-to)1439-1444
Number of pages6
JournalHaematologica
Volume109
Issue number5
DOIs
StatePublished - May 1 2024

Fingerprint

Dive into the research topics of 'Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study'. Together they form a unique fingerprint.

Cite this